| Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies BC Bernardo, KL Weeks, L Pretorius, JR McMullen Pharmacology & therapeutics 128 (1), 191-227, 2010 | 1173 | 2010 |
| Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets YK Tham, BC Bernardo, JYY Ooi, KL Weeks, JR McMullen Archives of toxicology 89, 1401-1438, 2015 | 767 | 2015 |
| Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways K Huynh, BC Bernardo, JR McMullen, RH Ritchie Pharmacology & therapeutics 142 (3), 375-415, 2014 | 630 | 2014 |
| Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function BC Bernardo, XM Gao, CE Winbanks, EJH Boey, YK Tham, H Kiriazis, ... Proceedings of the National Academy of Sciences 109 (43), 17615-17620, 2012 | 479 | 2012 |
| miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart BC Bernardo, JYY Ooi, RCY Lin, JR McMullen Future medicinal chemistry 7 (13), 1771-1792, 2015 | 261 | 2015 |
| The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass CE Winbanks, JL Chen, H Qian, Y Liu, BC Bernardo, C Beyer, KI Watt, ... Journal of Cell Biology 203 (2), 345-357, 2013 | 219 | 2013 |
| PI3K (p110α) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA RCY Lin, KL Weeks, XM Gao, RBH Williams, BC Bernardo, H Kiriazis, ... Arteriosclerosis, thrombosis, and vascular biology 30 (4), 724-732, 2010 | 200 | 2010 |
| The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy JYY Ooi, BC Bernardo, JR McMullen Future medicinal chemistry 6 (2), 205-222, 2014 | 142 | 2014 |
| Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts BC Bernardo, JYY Ooi, KL Weeks, NL Patterson, JR McMullen Physiological Reviews 98 (1), 419-475, 2018 | 141 | 2018 |
| Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction KL Weeks, X Gao, XJ Du, EJH Boey, A Matsumoto, BC Bernardo, ... Circulation: Heart Failure 5 (4), 523-534, 2012 | 140 | 2012 |
| A microRNA guide for clinicians and basic scientists: background and experimental techniques BC Bernardo, FJ Charchar, RCY Lin, JR McMullen Heart, Lung and Circulation 21 (3), 131-142, 2012 | 135 | 2012 |
| Changes in the chondrocyte and extracellular matrix proteome during post-natal mouse cartilage development R Wilson, E Norris, B Brachvogel, C Angelucci, S Zivkovic, L Gordon, ... Molecular & Cellular Proteomics, 2011 | 115 | 2011 |
| The IGF1-PI3K-Akt signaling pathway in mediating exercise-induced cardiac hypertrophy and protection KL Weeks, BC Bernardo, JYY Ooi, NL Patterson, JR McMullen Exercise for cardiovascular disease prevention and treatment: from molecular …, 2017 | 102 | 2017 |
| Enhanced phosphoinositide 3-kinase (p110α) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes RH Ritchie, JE Love, K Huynh, BC Bernardo, DC Henstridge, H Kiriazis, ... Diabetologia 55, 3369-3381, 2012 | 101 | 2012 |
| The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice G Sapra, YK Tham, N Cemerlang, A Matsumoto, H Kiriazis, BC Bernardo, ... Nature communications 5 (1), 5705, 2014 | 96 | 2014 |
| Cartilage intermediate layer protein 2 (CILP-2) is expressed in articular and meniscal cartilage and down-regulated in experimental osteoarthritis BC Bernardo, D Belluoccio, L Rowley, CB Little, U Hansen, JF Bateman Journal of Biological Chemistry 286 (43), 37758-37767, 2011 | 93 | 2011 |
| Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice CE Winbanks, KT Murphy, BC Bernardo, H Qian, Y Liu, PV Sepulveda, ... Science translational medicine 8 (348), 348ra98-348ra98, 2016 | 84 | 2016 |
| Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy BC Bernardo, XM Gao, YK Tham, H Kiriazis, CE Winbanks, JYY Ooi, ... PloS one 9 (2), e90337, 2014 | 83 | 2014 |
| Therapeutic silencing of miR‐652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy BC Bernardo, SS Nguyen, CE Winbanks, XM Gao, EJH Boey, YK Tham, ... The FASEB Journal 28 (12), 5097-5110, 2014 | 82 | 2014 |
| Identification of miR-34 regulatory networks in settings of disease and antimiR-therapy: Implications for treating cardiac pathology and other diseases JYY Ooi, BC Bernardo, S Singla, NL Patterson, RCY Lin, JR McMullen RNA biology 14 (5), 500-513, 2017 | 53 | 2017 |
Kate L Weeks, PhDUniversity of Melbourne在 unimelb.edu.au 的电子邮件经过验证
Kate L Weeks, PhDUniversity of Melbourne在 unimelb.edu.au 的电子邮件经过验证
Ruby CY LinWestmead Institute for Medical Research在 unsw.edu.au 的电子邮件经过验证